Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
About the study
The purpose of this study is to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
key inclusion Criteria:
- History of at least 5 attacks of migraine
- ≥ 15 headache days of which ≥ 8 headache days meet criteria as migraine days during the baseline period
- >=80% diary compliance during the baseline period
EXCLUSION CRITERIA
Key exclusion Criteria:
- Older than 50 years of age at migraine onset
- History of cluster or hemiplegic headache
- Evidence of seizure or major psychiatric disorder
- Cardiac or active hepatic disease
- Pregnant or nursing
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Migraine
Age (in years)
18 - 65
Phase
Phase 3
Participants needed
557
Est. Completion Date
Jun 28, 2024
Treatment type
Interventional
Sponsor
Novartis
ClinicalTrials.gov identifier
NCT03867201
Study number
CAMG334A2304
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?